2021 was a landmark year for clinical readouts within the oncolytic virotherapy field, and now OV developers are poised and ready at the cusp of something remarkable and this promising therapeutic is set to be a critical modality within cancer immunotherapy. With rapid advances in this compelling therapeutic, the Oncolytic Virotherapy Summit returns this December 2022 for its 7th edition.

As a leading industry forum, leading global biopharma will unite once again for three days dedicated to all things OV, as experts showcase clinical case studies and lead us through discussions to uncover the critical bottlenecks preventing widespread patient treatment with this promising therapeutic

What did we see in 2022? 

• • Clinical Case Study presentations from global biopharma leaders, ensuring you remain ahead of the curve of the latest breakthroughs
  • Interactive discussions and conversations led by true thought leaders into OV selection and combination therapy considerations
  • Dedicated deep-dive workshops delving into the CMC, Quality Control, Manufacturing Policy and Regulatory Guidance
  • Showcasing expertise and insights from leading pharmaceutical experts from Amgen, Boehringer Ingelheim, Astellas and Bristol Myers Squibb as they navigate the world of licensing and partnering for OV’s